Top

Cancer Causes & Control

Published in:

01-07-2015 | Brief report

Sleep duration and cancer risk in women

Authors: Susan Hurley, Debbie Goldberg, Leslie Bernstein, Peggy Reynolds

Published in: Cancer Causes & Control | Issue 7/2015

Abstract

Purpose

The objective was to conduct an analysis of sleep duration and risk of selected site-specific and groups of cancer among a large prospective cohort of California women.

Methods

The study population was comprised of 101,609 adult females participating in the California Teachers Study. All sites of invasive cancer prospectively diagnosed from baseline (1995–1996) through 2011 were identified through linkage to the California Cancer Registry (n = 12,322). Site-specific analyses focused on the following cancers: breast (n = 5,053), colorectal (n = 983), lung (n = 820), melanoma (n = 749), and endometrial (n = 957). Additionally, we evaluated a group of estrogen-mediated cancers consisting of breast, endometrial, and ovarian cancer (n = 6,458). Sleep duration was based on self-report of average time sleeping in the year prior to baseline. Cox proportional hazard models were used to calculate adjusted hazard ratios and 95 % confidence intervals (HRs, 95 % CI).

Results

Point estimates for all sites and site-specific cancers generally were near or below one for short sleepers (<6 h/night) and above one for long sleepers (10+ h/night); confidence intervals, however, were wide and included unity. Compared to average sleepers (7–9 h/night), long sleepers had an increased risk of the group of estrogen-mediated cancers (HR 1.22, 95 % CI 0.97–1.54, p (trend) = 0.04).

Conclusions

These analyses suggest that longer sleep may be associated with increased risks of estrogen-mediated cancers. Further studies with more refined measures of sleep duration and quality are warranted.

Ferrie JE, Kumari M, Salo P, Singh-Manoux A, Kivimaki M (2011) Sleep epidemiology—a rapidly growing field. Int J Epidemiol 40(6):1431–1437. doi:10.1093/ije/dyr203 PubMedCentralPubMedCrossRef

Irwin MR (2014) Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol. doi:10.1146/annurev-psych-010213-115205 PubMed

Institute of Medicine (2006) Sleep disorders and sleep deprivation: an unmet public health problem. The National Academies Press, Washington

Centers for Disease Control and Prevention Insufficient Sleep is a Public Health Epidemic. http://www.cdc.gov/features/dssleep/. Accessed 1 Oct 2014

Blask DE (2009) Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 13(4):257–264PubMedCrossRef

Chandola T, Ferrie JE, Perski A, Akbaraly T, Marmot MG (2010) The effect of short sleep duration on coronary heart disease risk is greatest among those with sleep disturbance: a prospective study from the Whitehall II cohort. Sleep 33(6):739–744PubMedCentralPubMed

Heianza Y, Kato K, Fujihara K, Tanaka S, Kodama S, Hanyu O, Sato K, Sone H (2014) Role of sleep duration as a risk factor for Type 2 diabetes among adults of different ages in Japan: the Niigata Wellness Study. Diabet Med. doi:10.1111/dme.12555

Lehrer S, Green S, Ramanathan L, Rosenzweig KE (2013) Obesity and deranged sleep are independently associated with increased cancer mortality in 50 US states and the District of Columbia. Sleep Breath 17(3):1117–1118. doi:10.1007/s11325-013-0811-x PubMedCrossRef

Lu Y, Tian N, Yin J, Shi Y, Huang Z (2013) Association between sleep duration and cancer risk: a meta-analysis of prospective cohort studies. PLoS ONE 8(9):e74723. doi:10.1371/journal.pone.0074723 PubMedCentralPubMedCrossRef

10.

Lucassen EA, Rother KI, Cizza G (2012) Interacting epidemics? Sleep curtailment, insulin resistance, and obesity. Ann N Y Acad Sci 1264:110–134. doi:10.1111/j.1749-6632.2012.06655.x PubMedCentralPubMedCrossRef

11.

Qin Y, Zhou Y, Zhang X, Wei X, He J (2014) Sleep duration and breast cancer risk: a meta-analysis of observational studies. Int J Cancer 134(5):1166–1173. doi:10.1002/ijc.28452 PubMedCrossRef

12.

Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A (2009) Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep 32(4):491–497PubMedCentralPubMed

13.

Zhao H, Yin JY, Yang WS, Qin Q, Li TT, Shi Y, Deng Q, Wei S, Liu L, Wang X, Nie SF (2013) Sleep duration and cancer risk: a systematic review and meta-analysis of prospective studies. Asian Pac J Cancer Prev 14(12):7509–7515PubMedCrossRef

14.

Carter BD, Diver WR, Hildebrand JS, Patel AV, Gapstur SM (2014) Circadian disruption and fatal ovarian cancer. Am J Prev Med 46(3 Suppl 1):S34–S41. doi:10.1016/j.amepre.2013.10.032 PubMedCrossRef

15.

Girschik J, Heyworth J, Fritschi L (2013) Self-reported sleep duration, sleep quality, and breast cancer risk in a population-based case–control study. Am J Epidemiol 177(4):316–327. doi:10.1093/aje/kws422 PubMedCrossRef

16.

Hu LY, Chen PM, Hu YW, Shen CC, Perng CL, Su TP, Yen SH, Tzeng CH, Chiou TJ, Yeh CM, Chen TJ, Wang WS, Liu CJ (2013) The risk of cancer among patients with sleep disturbance: a nationwide retrospective study in Taiwan. Ann Epidemiol 23(12):757–761PubMedCrossRef

17.

Jiao L, Duan Z, Sangi-Haghpeykar H, Hale L, White DL, El-Serag HB (2013) Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer 108(1):213–221. doi:10.1038/bjc.2012.561 PubMedCentralPubMedCrossRef

18.

Kakizaki M, Inoue K, Kuriyama S, Sone T, Matsuda-Ohmori K, Nakaya N, Fukudo S, Tsuji I (2008) Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. Br J Cancer 99(1):176–178. doi:10.1038/sj.bjc.6604425 PubMedCentralPubMedCrossRef

19.

Kakizaki M, Kuriyama S, Sone T, Ohmori-Matsuda K, Hozawa A, Nakaya N, Fukudo S, Tsuji I (2008) Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer 99(9):1502–1505. doi:10.1038/sj.bjc.6604684 PubMedCentralPubMedCrossRef

20.

Khawaja A, Rao S, Li L, Thompson CL (2013) Sleep duration and breast cancer phenotype. J Cancer Epidemiol 2013:467927. doi:10.1155/2013/467927 PubMedCentralPubMedCrossRef

21.

Luo J, Sands M, Wactawski-Wende J, Song Y, Margolis KL (2013) Sleep disturbance and incidence of thyroid cancer in postmenopausal women the Women’s Health Initiative. Am J Epidemiol 177(1):42–49. doi:10.1093/aje/kws193 PubMedCentralPubMedCrossRef

22.

McElroy JA, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, Egan KM (2006) Duration of sleep and breast cancer risk in a large population-based case–control study. J Sleep Res 15(3):241–249PubMedCrossRef

23.

Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66(10):5521–5525PubMedCrossRef

24.

Sturgeon SR, Luisi N, Balasubramanian R, Reeves KW (2012) Sleep duration and endometrial cancer risk. Cancer Causes Control 23(4):547–553. doi:10.1007/s10552-012-9912-2 PubMedCrossRef

25.

Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, Kaprio J (2005) Sleep duration and breast cancer: a prospective cohort study. Cancer Res 65(20):9595–9600PubMedCrossRef

26.

Vogtmann E, Levitan EB, Hale L, Shikany JM, Shah NA, Endeshaw Y, Lewis CE, Manson JE, Chlebowski RT (2013) Association between sleep and breast cancer incidence among postmenopausal women in the Women’s Health Initiative. Sleep 36(10):1437–1444. doi:10.5665/sleep.3032 PubMedCentralPubMed

27.

von Ruesten A, Weikert C, Fietze I, Boeing H (2012) Association of sleep duration with chronic diseases in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. PLoS ONE 7(1):e30972. doi:10.1371/journal.pone.0030972 CrossRef

28.

Weiderpass E, Sandin S, Inoue M, Shimazu T, Iwasaki M, Sasazuki S, Sawada N, Yamaji T, Tsugane S (2012) Risk factors for epithelial ovarian cancer in Japan—results from the Japan Public Health Center-based Prospective Study cohort. Int J Oncol 40(1):21–30. doi:10.3892/ijo.2011.1194 PubMed

29.

Wu AH, Stanczyk FZ, Wang R, Koh WP, Yuan JM, Yu MC (2013) Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. Int J Cancer 132(4):891–896. doi:10.1002/ijc.27653 PubMedCentralPubMedCrossRef

30.

Wu AH, Wang R, Koh WP, Stanczyk FZ, Lee HP, Yu MC (2008) Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 29(6):1244–1248PubMedCentralPubMedCrossRef

31.

Zhang X, Giovannucci EL, Wu K, Gao X, Hu F, Ogino S, Schernhammer ES, Fuchs CS, Redline S, Willett WC, Ma J (2013) Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women. Sleep 36(5):681–688. doi:10.5665/sleep.2626 PubMedCentralPubMed

32.

Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21(3):427–433PubMedCrossRef

33.

Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Pinder R, Reynolds P, Sullivan-Halley J, West D, Wright W, Ziogas A, Ross RK (2002) High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 13(7):625–635PubMedCrossRef

34.

California Cancer Registry. http://www.ccrcal.org/abouttheccr.html. Accessed 25 Sept 2014

35.

Hurley S, Nelson DO, Garcia E, Gunier R, Hertz A, Reynolds P (2013) A cross-sectional analysis of light at night, neighborhood sociodemographics and urinary 6-sulfatoxymelatonin concentrations: implications for the conduct of health studies. Int J Health Geogr 12:39. doi:10.1186/1476-072X-12-39 PubMedCentralPubMedCrossRef

36.

Reynolds P, Hurley SE, Quach AT, Rosen H, Von Behren J, Hertz A, Smith D (2005) Regional variations in breast cancer incidence among California women, 1988–1997. Cancer Causes Control 16(2):139–150. doi:10.1007/s10552-004-2616-5 PubMedCrossRef

37.

Walter S, Tiemeier H (2009) Variable selection: current practice in epidemiological studies. Eur J Epidemiol 24(12):733–736. doi:10.1007/s10654-009-9411-2 PubMedCentralPubMedCrossRef

38.

Patel SR, Ayas NT, Malhotra MR, White DP, Schernhammer ES, Speizer FE, Stampfer MJ, Hu FB (2004) A prospective study of sleep duration and mortality risk in women. Sleep 27(3):440–444PubMed

39.

Patel SR, Blackwell T, Ancoli-Israel S, Stone KL (2012) Sleep characteristics of self-reported long sleepers. Sleep 35(5):641–648. doi:10.5665/sleep.1822 PubMedCentralPubMed

40.

Stevens RG (2009) Working against our endogenous circadian clock: breast cancer and electric lighting in the modern world. Mutat Res 679(1–2):6–8

41.

Ayas NT, White DP, Al-Delaimy WK, Manson JE, Stampfer MJ, Speizer FE, Patel S, Hu FB (2003) A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care 26(2):380–384PubMedCrossRef

42.

Nock NL, Li L, Larkin EK, Patel SR, Redline S (2009) Empirical evidence for “syndrome Z”: a hierarchical 5-factor model of the metabolic syndrome incorporating sleep disturbance measures. Sleep 32(5):615–622PubMedCentralPubMed

43.

Patel SR, Blackwell T, Redline S, Ancoli-Israel S, Cauley JA, Hillier TA, Lewis CE, Orwoll ES, Stefanick ML, Taylor BC, Yaffe K, Stone KL (2008) The association between sleep duration and obesity in older adults. Int J Obes (Lond) 32(12):1825–1834. doi:10.1038/ijo.2008.198 PubMedCentralCrossRef

44.

Aeschbach D, Sher L, Postolache TT, Matthews JR, Jackson MA, Wehr TA (2003) A longer biological night in long sleepers than in short sleepers. J Clin Endocrinol Metab 88(1):26–30. doi:10.1210/jc.2002-020827 PubMedCrossRef

45.

Anisimov VN (2003) The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 46(3):221–234PubMedCrossRef

46.

Reiter RJ (2004) Mechanisms of cancer inhibition by melatonin. J Pineal Res 37(3):213–214PubMedCrossRef

Title: Sleep duration and cancer risk in women
Authors: Susan Hurley
Debbie Goldberg
Leslie Bernstein
Peggy Reynolds
Publication date: 01-07-2015
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 7/2015
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-015-0579-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2015

Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy, and childhood acute leukemia: the ESTELLE study

Effects of active, passive, and combined smoking on cervical cancer mortality: a nationwide proportional mortality study in Chinese urban women

Chronic diseases, medical history and familial cancer, and risk of leukemia and non-Hodgkin’s lymphoma in an adult population: a case–control study

Even anti-tobacco studies must be held to basic scientific standards. A response to: Smoking intensity and intent to continue smoking among menthol and non-menthol adolescent smokers in Canada

Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case–control study

Association between plasma adiponectin levels and colorectal cancer risk in women

Keynote webinar | Spotlight on antibody–drug conjugates in cancer